JP2017106923A5 - - Google Patents

Download PDF

Info

Publication number
JP2017106923A5
JP2017106923A5 JP2016243869A JP2016243869A JP2017106923A5 JP 2017106923 A5 JP2017106923 A5 JP 2017106923A5 JP 2016243869 A JP2016243869 A JP 2016243869A JP 2016243869 A JP2016243869 A JP 2016243869A JP 2017106923 A5 JP2017106923 A5 JP 2017106923A5
Authority
JP
Japan
Prior art keywords
cancer
protein
sample
treatment
modulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016243869A
Other languages
English (en)
Japanese (ja)
Other versions
JP6580546B2 (ja
JP2017106923A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017106923A publication Critical patent/JP2017106923A/ja
Publication of JP2017106923A5 publication Critical patent/JP2017106923A5/ja
Application granted granted Critical
Publication of JP6580546B2 publication Critical patent/JP6580546B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016243869A 2010-04-19 2016-12-16 薬物感受性、薬物抵抗性および疾患進行の予測のための組成物および方法 Expired - Fee Related JP6580546B2 (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US32571710P 2010-04-19 2010-04-19
US61/325,717 2010-04-19
US35649510P 2010-06-18 2010-06-18
US61/356,495 2010-06-18
US42117810P 2010-12-08 2010-12-08
US61/421,178 2010-12-08
US201161443146P 2011-02-15 2011-02-15
US61/443,146 2011-02-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013506214A Division JP6158078B2 (ja) 2010-04-19 2011-04-18 薬物感受性、薬物抵抗性および疾患進行の予測のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2017106923A JP2017106923A (ja) 2017-06-15
JP2017106923A5 true JP2017106923A5 (enExample) 2017-09-14
JP6580546B2 JP6580546B2 (ja) 2019-09-25

Family

ID=44834747

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013506214A Expired - Fee Related JP6158078B2 (ja) 2010-04-19 2011-04-18 薬物感受性、薬物抵抗性および疾患進行の予測のための組成物および方法
JP2016243869A Expired - Fee Related JP6580546B2 (ja) 2010-04-19 2016-12-16 薬物感受性、薬物抵抗性および疾患進行の予測のための組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013506214A Expired - Fee Related JP6158078B2 (ja) 2010-04-19 2011-04-18 薬物感受性、薬物抵抗性および疾患進行の予測のための組成物および方法

Country Status (12)

Country Link
US (1) US9766249B2 (enExample)
EP (1) EP2561368B1 (enExample)
JP (2) JP6158078B2 (enExample)
KR (1) KR101977875B1 (enExample)
CN (2) CN102947706B (enExample)
AU (1) AU2011242990B2 (enExample)
CA (1) CA2795362C (enExample)
ES (1) ES2650674T3 (enExample)
HK (1) HK1258688A1 (enExample)
PL (1) PL2561368T3 (enExample)
SG (1) SG184507A1 (enExample)
WO (1) WO2011133477A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2294216A4 (en) 2008-05-14 2011-11-23 Dermtech Int DIAGNOSIS OF MELANOMA AND SOLAR LENTIGO BY ANALYSIS OF NUCLEIC ACIDS
CA2767616A1 (en) 2009-07-09 2011-01-13 The Scripps Research Institute Gene expression profiles associated with chronic allograft nephropathy
WO2014145705A2 (en) 2013-03-15 2014-09-18 Battelle Memorial Institute Progression analytics system
CN104152397A (zh) * 2013-05-13 2014-11-19 复旦大学 一种致敏动物的脾细胞模型及其在药物筛选中的用途
GB201314485D0 (en) * 2013-08-13 2013-09-25 Electrophoretics Ltd Materials and methods relating to pancreatic cancer
TW201601753A (zh) * 2013-09-30 2016-01-16 第一三共股份有限公司 蛋白質生物標記及其用途
WO2022187196A1 (en) * 2021-03-02 2022-09-09 Dermtech, Inc. Predicting therapeutic response
US11578373B2 (en) 2019-03-26 2023-02-14 Dermtech, Inc. Gene classifiers and uses thereof in skin cancers
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
US11104951B2 (en) 2014-05-22 2021-08-31 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
CN104745700A (zh) * 2015-03-27 2015-07-01 南京医科大学 一种食管癌相关甲基化生物标志物及应用
CN107922504B (zh) * 2015-07-07 2021-07-30 豪夫迈·罗氏有限公司 抗HER2抗体-药物缀合物和Bcl-2抑制剂的组合疗法
WO2017136603A1 (en) * 2016-02-02 2017-08-10 Guardant Health, Inc. Cancer evolution detection and diagnostic
CN105524973A (zh) * 2016-03-15 2016-04-27 南京华奥生物医药技术有限公司 利用自体肿瘤与正常配对原代细胞筛选肿瘤药物的方法
CN107091930B (zh) * 2017-03-07 2020-09-15 杭州百凌生物科技有限公司 快速预测和提高非小细胞肺癌细胞对表皮细胞生长因子受体抑制剂敏感性的方法
CN107271672B (zh) * 2017-06-21 2019-01-01 首都医科大学附属北京友谊医院 外泌体p-ERK在制备结直肠癌诊断产品中的应用
KR102094802B1 (ko) * 2017-10-24 2020-03-31 고려대학교 산학협력단 소변 대사체 분석을 이용한 베체트병의 진단방법
CN111417730A (zh) * 2017-11-20 2020-07-14 托雷莫治疗股份公司 诊断方法
TWI683905B (zh) * 2017-11-21 2020-02-01 長庚醫療財團法人高雄長庚紀念醫院 用於檢測川崎氏病的方法及套組以及用於治療川崎氏病的方法
US11976332B2 (en) 2018-02-14 2024-05-07 Dermtech, Inc. Gene classifiers and uses thereof in non-melanoma skin cancers
KR102199141B1 (ko) 2019-05-03 2021-01-06 사회복지법인 삼성생명공익재단 대장암 진단 마커 및 대장암 진단에 필요한 정보를 제공하는 방법
EP4185870A1 (en) * 2020-07-24 2023-05-31 Genentech, Inc. Determining hemodilution of bone marrow aspirates using biomarkers
CN115267165A (zh) * 2022-08-15 2022-11-01 海仕兰(上海)生物科技有限公司 一种悬浮芯片系统及其应用以及基于悬浮芯片系统对肿瘤伴随诊断因子检测方法
KR20240037082A (ko) * 2022-09-14 2024-03-21 아주대학교산학협력단 항암제 내성 측정용 바이오 마커 및 이를 이용한 항암제 내성 예측 정보 제공 방법
CN118130793B (zh) * 2024-02-26 2025-07-29 赣南医科大学 视网膜母细胞瘤的生物标志物cdk12及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US20060188895A1 (en) * 2004-08-31 2006-08-24 The Johns Hopkins University Rapid prognostic assay for malignancies treated with epidermal growth factor receptor
US8841076B2 (en) * 2005-05-09 2014-09-23 Theranos, Inc. Systems and methods for conducting animal studies
WO2006125143A2 (en) * 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
WO2006133399A1 (en) 2005-06-08 2006-12-14 Hitachi Chemical Research Center, Inc. METHOD FOR PREDICTING IMMUNE RESPONSE TO NEOPLASTIC DISEASE BASED ON mRNA EXPRESSION PROFILE IN NEOPLASTIC CELLS AND STIMULATED LEUKOCYTES
EP1937314A4 (en) 2005-09-01 2009-01-07 Bristol Myers Squibb Co BIOMARKERS AND PROCEDURE FOR DETERMINING SENSITIVITY FOR VASCULAR ENDOTHEL GROWTH FACTOR RECEPTOR 2 MODULATORS
WO2007143183A2 (en) 2006-06-04 2007-12-13 Soner Altiok Methods for developing and assessing therapeutic agents
PE20090681A1 (es) * 2007-03-02 2009-06-10 Genentech Inc Prediccion de respuesta a un inhibidor her
JP2010536371A (ja) * 2007-08-21 2010-12-02 ノダリティ,インコーポレイテッド 診断方法、予後および治療方法
EP2210080B1 (en) 2007-10-24 2015-01-28 Biomarker Strategies, Llc Improved methods and devices for cellular analysis
EP2220503A1 (en) * 2007-11-30 2010-08-25 Schering Corporation Braf biomarkers

Similar Documents

Publication Publication Date Title
JP2017106923A5 (enExample)
Yankaskas et al. A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens
Liu et al. DNA-methylation-mediated silencing of miR-486-5p promotes colorectal cancer proliferation and migration through activation of PLAGL2/IGF2/β-catenin signal pathways
Grottke et al. Downregulation of AKT3 increases migration and metastasis in triple negative breast cancer cells by upregulating S100A4
Xia et al. Exosome‐mediated transfer of miR‐1260b promotes cell invasion through Wnt/β–catenin signaling pathway in lung adenocarcinoma
JP2016507233A5 (enExample)
Miyamoto et al. Single-cell analysis of circulating tumor cells as a window into tumor heterogeneity
Bhandari et al. MAL2 promotes proliferation, migration, and invasion through regulating epithelial-mesenchymal transition in breast cancer cell lines
Lin et al. Knockdown of OCT4 suppresses the growth and invasion of pancreatic cancer cells through inhibition of the AKT pathway
Yan et al. LASP1 interacts with N-WASP to activate the Arp2/3 complex and facilitate colorectal cancer metastasis by increasing tumour budding and worsening the pattern of invasion
JP2019534321A5 (enExample)
Qu et al. Long non-coding RNA ROR is a novel prognosis factor associated with non-small-cell lung cancer progression
CN104805197A (zh) 分子标志物用于乳腺癌诊断和预后评估的方法
He et al. HOXA13 upregulation in gastric cancer is associated with enhanced cancer cell invasion and epithelial-to-mesenchymal transition.
Jiang et al. Low FAT4 expression is associated with a poor prognosis in gastric cancer patients
JP2015210268A5 (enExample)
Jeong et al. Morphology-guided transcriptomic analysis of human pancreatic cancer organoids reveals microenvironmental signals that enhance invasion
Zhai et al. Overexpressed versican promoted cell multiplication, migration and invasion in gastric cancer
Yang et al. RETRACTED ARTICLE: Long Noncoding RNA KCNMB2-AS1 Increases ROCK1 Expression by Sponging microRNA-374a-3p to Facilitate the Progression of Non–Small-Cell Lung Cancer
Jin et al. Endoplasmic reticulum–resident protein Sec62 drives colorectal cancer metastasis via MAPK/ATF2/UCA1 axis
Wu et al. Organoid models: applications and research advances in colorectal cancer
ES2891795T3 (es) Procedimiento y kit para el diagnóstico de cáncer colorrectal
CN107937520B (zh) 与结直肠癌相关的分子标记物、抑制剂、试剂盒和药剂
Bahadoran et al. Cytokeratin expression in breast cancer: from mechanisms, progression, diagnosis, and prognosis to therapeutic implications
Li et al. Overexpression of Aldo-keto reductase family 1 B10 protein in ductal carcinoma in situ of the breast correlates with HER2 positivity